New Path Molecular Research Limited

Product: 
Life Sciences
Status: 
Closed
Sector: 
Molecule research
Aim of funding: 
Seed
HMRC Advance Assurance received: 
Yes

New Path Molecular Research Limited

Description: 

The Company was established in January 2015 by Professor Steven Ley at the University of Cambridge, following his observation that, due to industry developments such as the reduction in internal R&D spending and out-sourcing to low cost economies, access to the most creative and innovative chemistry was becoming constrained. A consequence of outsourcing has been to reduce chemical innovation in small molecule research.

The Company is focused therefore on the provision of contract research services for small molecule research, utilising a unique hybrid model of identifying chemical and biological entities.  This approach enables costs of manufacturing to be reduced as chemicals are cheaper than biological products.

The Company’s clients are typically ‘virtual’ discovery companies (i.e. with no internal chemistry resource) and also large pharma companies with an interest in a particular ‘New Path’ technology area.

The hybrid models takes risk out of introducing a new way of identifying chemical entities that would replace targeted therapies known as biologicals. The company's platform technology also enables the exponentially improving cost of manufacturing because chemicals are much cheaper to manufacture than biological products. 

Opportunity: 

Research and Development expenditure by chemical businesses in the UK is £612m and pharmaceutical businesses is £4.1bn.

Historically, the synthesis of chemicals has had a huge impact on human technological progress. For example, synthetic chemicals are a key component of 60% of medicines, > 90% of agrochemicals, >90% of coatings, 100% of propellants, 100% of performance materials, 100% of batteries, 100% of photoresists (materials used in making microcircuits)and oLEDs (‘organic light emitting diodes used in TVs for example), and 100% of fuels and lubricants.

The ability to make, test and improve the design of these ‘functional’ molecules is a major step in the exploitation of discoveries in genetics, renewable energy, electronics, material science and biology. In effect, it is only by using the creative science of synthetic chemistry that these discoveries can be translated into economic and humanitarian benefits.

Information on this webpage relates to and is provided by Deepbridge Advisers Limited.

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Deepbridge Capital LLP, Deepbridge Advisers Limited and Enterprise Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.